Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients Wit...
For patients who do not have a tumor recurrence or death, DFS will be censored on the date of last disease assessment.
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Intratumoral CD3+ T-cells will be identified by immunohistochemistry in pre- and post-treatment tumor specimens. The analysis population for the primary outcome will be all patients who received at least 2 weeks of neoadjuvant the...
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants...
The occurrence of the following toxicities, if assessed by the investigator to be possibly, probably, or definitely related to study treatment administration: Grade 4 nonhematologic toxicity (not laboratory) Grade 4 hematologic ...
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
Measured using RECIST 1.1
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head...